Viatris (VTRS) Cash from Financing Activities (2019 - 2026)

Viatris (VTRS) recorded quarterly Cash from Financing Activities of -$203.8 million in Q1 2026, up 13.79% quarter-over-quarter from -$236.4 million in Q4 2025, and up 56.36% on a YoY basis from -$130.3 million in Q1 2025.

Viatris (VTRS) Cash from Financing Activities (2019 - 2026) Analysis & Trends

Viatris' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at -$203.8 million for Q1 2026.

  • In Q1 2026, Cash from Financing Activities rose 56.36% year-over-year to -$203.8 million; the TTM figure through Mar 2026 stood at -$1.0 billion (up 76.42% YoY), while the FY2025 annual figure was -$1.3 billion, up 70.12% from the prior year.
  • Cash from Financing Activities was -$203.8 million for Q1 2026 at Viatris, up from -$236.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of -$97.6 million in Q3 2023 to a low of -$1.6 billion in Q3 2024.
  • Historically, Cash from Financing Activities has averaged -$706.3 million across 5 years, with a median of -$758.7 million in 2022.
  • The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities surged 87.14% in 2023, then plunged 1576.95% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at -$1.3 billion in 2022, then surged by 30.4% to -$926.1 million in 2023, then plunged by 53.35% to -$1.4 billion in 2024, then surged by 83.35% to -$236.4 million in 2025, then increased by 13.79% to -$203.8 million in 2026.
  • The last three Cash from Financing Activities figures came in at -$203.8 million (Q1 2026), -$236.4 million (Q4 2025), and -$228.1 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 13.00 Mn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn -840.00 Mn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn -1.48 Bn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn -86.10 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn -65.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 1.47 Bn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -77.88 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn -11.62 Mn
10 Viatris - - 1.16 Bn -203.80 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -203.80 Mn
Mar 31, 2026 -203.80 Mn
Dec 31, 2025 -236.40 Mn
Dec 31, 2025 -236.40 Mn
Sep 30, 2025 -228.10 Mn
Sep 30, 2025 -228.10 Mn
Jun 30, 2025 -362.40 Mn
Jun 30, 2025 -362.40 Mn
Mar 31, 2025 -467.00 Mn
Mar 31, 2025 -467.00 Mn
Dec 31, 2024 -1.42 Bn
Dec 31, 2024 -1.42 Bn
Sep 30, 2024 -1.64 Bn
Sep 30, 2024 -1.64 Bn
Jun 30, 2024 -847.90 Mn
Jun 30, 2024 -847.90 Mn
Mar 31, 2024 -425.60 Mn
Mar 31, 2024 -425.60 Mn
Dec 31, 2023 -926.10 Mn
Dec 31, 2023 -926.10 Mn